Cancer Therapy Effects on the Heart
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
Conditions:
🦠 Cardiotoxicity 🦠 Pediatric Cancer 🦠 Heart Failure
🗓️ Study Start (Actual) 30 September 2019
🗓️ Primary Completion (Estimated) 30 September 2022
✅ Study Completion (Estimated) 30 September 2029
👥 Enrollment (Estimated) 60
🔬 Study Type OBSERVATIONAL
📊 Phase N/A
Locations:
📍 San Diego, California, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * English and Spanish speaking male and female subjects, ages 13-39 years old
    • * Diagnosis of cancer at age \<22 years
    • * Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior.

    Exclusion Criteria:

    • * Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants.
    • * Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia.
    • * Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus).
    • * Patients with orthodontic braces or metallic implants in the thorax or abdomen/lumbar spine, even if MRI-compatible, will be excluded as these may cause artifacts and limit image quality.
    • * Pregnancy.
Ages Eligible for Study: 13 Years to 39 Years (CHILD, ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 4 November 2019
  • First Submitted that Met QC Criteria 7 February 2020
  • First Posted 10 February 2020

Study Record Updates

  • Last Update Submitted that Met QC Criteria 27 April 2021
  • Last Update Posted 30 April 2021
  • Last Verified April 2021